Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CNG | ISIN: SE0002480442 | Ticker-Symbol: 9EE
Frankfurt
23.01.25
09:16 Uhr
9,070 Euro
+0,070
+0,78 %
Branche
Handel/E-Commerce
Aktienmarkt
Sonstige
1-Jahres-Chart
ZINZINO AB Chart 1 Jahr
5-Tage-Chart
ZINZINO AB 5-Tage-Chart
RealtimeGeldBriefZeit
9,2309,32023:00
9,2309,32022:00
PR Newswire
599 Leser
Artikel bewerten:
(2)

ZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA INITIATING CHAPTER 11 PROCESS

Finanznachrichten News

GOTHENBURG, Sweden, Dec. 22, 2024 /PRNewswire/ -- Zinzino has in a press release dated 20240617 announced that a letter of intent to acquire 100% of the shares in the North American direct selling company Zurvita Inc. "Zurvita or the Company" was signed. Since then, Zinzino has negotiated with the owners of Zurvita Inc. and instead concluded that the purchase of Zurvita's assets in a Chapter 11 proceeding for the Company is in Zinzino's best interest.

Zinzino is providing a debtor-in-possession (DIP) financing to Zurvita, which filed for Chapter 11 bankruptcy proceedings on the 20th December 2024. By entering as a financier in Zurvita's Chapter 11 with loans totaling USD 4.5 million, Zinzino simultaneously makes an offer to acquire the company's assets via a so-called stalking horse bid. If the bid is accepted, the DIP loan will be converted into part of a debt-settled purchase price, which will be determined after Zurvita has completed the sale process that is subject to higher and better offers in accordance with the applicable terms of Chapter 11. Other bidders have the right to submit bids for Zurvita during the process and if another bid is accepted, Zinzino's loan will be repaid and certain of its costs associated with the process will be reimbursed.

Zurvita is a direct selling health company with operations in the United States, Canada and Mexico. The brand portfolio offers a range of innovative health and wellness products. The business has total annual sales of approximately USD 30 million with good gross margins. A potential transaction with Zinzino is expected to add growth through the synergies arising from the joint networks, combined with Zinzino's test-based product concept. The profitability of the Company will thus be able to develop well by utilizing Zinzino's existing technical platform and organization.

A visionary mindset, tech first perspective, test-based nutrition at the cellular level and a strong position to capitalize on current trends will form the basis of the new partnership. Following the acquisitions of VMA Life in 2020, Enhanzz in 2022, the strategic partnership with ACN and the recently completed asset acquisition of Xelliss, Zinzino has been looking for further strong investments to maintain its sustainable, profitable growth, strengthen its distribution power, expand into new markets and leverage the product portfolio in new consumer areas.

- "Individualized advice and tailored solutions are the future, and not just in health and wellness," says Dag Bergheim Pettersen, CEO of Zinzino. "Together, we have years of combined industry experience and everything it takes to drive the modern, personalized shopping experience through direct sales". Jay Shafer, CEO and co-founder of Zurvita, states "After considering multiple options for the company and under the guidance of our attorneys and third-party advisors, we feel this presents the best opportunity to continue Zurvita's mission, deliver the highest quality products, and provide continuity for our staff and consultants. We are excited to see what the future holds for Zurvita."

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, www.zinzino.com

Pictures for publication free of charge:
marketing@zinzino.com

Certified Adviser:
Carnegie Investment Bank AB (publ.)

Zinzino AB (publ.) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 20.00 on the 21st of December 2024.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--enters-into-agreement-to-provide-dip-financing-to-zurvita-initiating-chapter-11-pr,c4086040

The following files are available for download:

https://mb.cision.com/Public/10976/4086040/87be55e6a08f0551.pdf

Press-release-Zinzino-Zurvita-20241221

Cision View original content:https://www.prnewswire.co.uk/news-releases/zinzino-ab-publ-enters-into-agreement-to-provide-dip-financing-to-zurvita-initiating-chapter-11-process-302337945.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.